Nordic Issuing

Ongoing case

Modus Therapeutics Holding AB

Back to all cases

Modus Therapeutics Holding AB

19 May - 9 Jun 2022Warrant exercise

Modus is a clinical biotechnology company that, through the polysaccharide sevuparin, is developing a treatment for sepsis and septic shock – a serious and often fatal condition. Modus treatment is aimed at anyone suffering from sepsis or septic shock, and since there is no treatment available for these serious conditions, a future treatment places itself in a high-priced segment. The company’s primary focus is the upcoming clinical phase Ib-LPS provocation study in sepsis / septic shock and a clinical phase IIa-Proof-of-Concept study in sepsis / septic shock. Mode’s vision is to create an effective treatment for patients with sepsis and septic shock that binds and neutralizes the harmful substances secreted in the blood during hyperinflammation to stabilize the initial bacterial infection.

Read more on the company's website

The offer in summary

Exercise period: 19 May - 9 June 2022

Price per share: SEK 7.30

Trading with warrants: Until 7 June 2022

Emission volume: Maximum of 5 156 300 warrants of series TO 1

Payment day: 9 June 2022

Marketplace: First North Stockholm

Financial advisor: Sedermera Corporate Finance


Due to restrictions in applicable law in the United States, Canada, Australia, Hong Kong, Singapore, South Africa, Switzerland, New Zealand, Japan, Russia, Belarus or other countries where participation requires further prospectuses, registrations or actions other than those under Swedish law, the offer to subscribe for securities in this offer is not directed at persons or others with registered address in any of these countries.